Okuno, Taishi
Overtchouk, Pavel
Asami, Masahiko
Tomii, Daijiro
Stortecky, Stefan
Praz, Fabien
Lanz, Jonas
Siontis, George C. M.
Gräni, Christoph
Windecker, Stephan
Pilgrim, Thomas
Article History
Received: 8 April 2021
Accepted: 6 September 2021
First Online: 21 September 2021
Competing interests
: Dr. Overtchouk is the CEO of ALVISS.AI SAS. Dr. Windecker serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also member of the steering/excecutive committee group of several investigated-initiated trials that receive funding by industry without impact on his personal remuneration. Dr. Windecker is an unpaid member of the Pfizer Research Award selection committee in Switzerland. Dr. Pilgrim reports research grants to the institution from Edwards Lifesciences, Boston Scientifc and Biotronik, personal fees from Biotronik and Boston Scientific, and other from HighLife SAS. Dr. Okuno reports speaker fees from Abbott. All other authors have no relationships relevant to the contents of this article to disclose.